Sponsor & Developer Portfolio
AstraZeneca
Clinical development pipeline, platform architecture, and registered trial tracking for AstraZeneca vaccine candidates.
3
Candidates
3
Target Diseases
4
Linked Studies
Development Phase Distribution
Phase 2 Clinical Trial: 2 Discontinued / Inactive: 1
Platform Technologies
Biological (unspecified platform): 3
Target Pathogens & Indications
COVID-19 Influenza RSV
Vaccine Pipeline Candidates (3)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-azd1222-astrazeneca
AZD1222
Target: COVID-19
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2023-04-19 (registry estimate)
Phase 2 Clinical Trial
ctgov-azd4117-astrazeneca
AZD4117
Target: Influenza
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2026-01-28 (registry estimate)
Phase 2 Clinical Trial
ctgov-azd6489-astrazeneca
AZD6489
Target: RSV
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2026-10-01 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.